Chiesi’s commitment to planet and patient care
Chiesi's unwavering commitment to both patient care and environmental sustainability sets a new standard in the pharmaceutical industry.
Defence announces Dr Maxime Parisotto as CSO, Director of Science and Business Development
Dr Maxime Parisotto is a seasoned biochemist with over 20 years of experience spanning academic research, drug development, and innovation.
Oak Hill Bio and Chiesi enrol first European patient in bronchopulmonary dysplasia treatment study
Oak Hill Bio and Chiesi Group have launched a groundbreaking study of a revolutionary bronchopulmonary dysplasia treatment for extremely premature infants.
Oak Hill Bio, a...
Chiesi NICU campaign and documentary to raise awareness for premature births
Premature births disrupt the expected narrative of a pregnancy, intertwining vulnerability with resilience.
In their campaign, Unscripted Beginnings. A Fragile Start, a Strong Future, Chiesi...
Chiesi places 23rd in 2024 World’s Best Workplaces™ List
This is the first time that Chiesi has been included in the GPTW global list, making it the first Italian company to achieve this honour.
Defence Therapeutics welcomes Dr Svetlana Selivanova to board of directors
Defence Therapeutics Inc., a Canadian biopharmaceutical company specialising in radiopharmaceuticals, antibody-drug conjugates (ADC), and immune-oncology vaccines, has announced that Dr Svetlana Selivanova has joined...
Chiesi Group’s new Biotech Center of Excellence brings the future of medicine to Parma
Chiesi Group is making a strategic investment of € 400 million to establish its new Biotech Center of Excellence in Parma.
Chiesi Group, an international...
Laura Vergani joins Chiesi Group to lead global communications & public affairs
Laura Vergani has joined Chiesi Group this week as Senior Vice President of Global Communications & Public Affairs.
Defence Therapeutics advances radio-immuno-conjugates with CNRI-H Program approval
Defence Therapeutics Inc. has announced a significant milestone in its radio-immuno-conjugates project.
The Canadian Nuclear Research Initiative Health (CNRI-H) Program application by Defence Therapeutics has...
Chiesi Group releases 2023 sustainability report
Chiesi, an international biopharmaceutical group, has published its 2023 sustainability report. Find out more.
Defence Receives No Objection Letter from Health Canada for Phase I Trial of ACCUM-002...
Defence Therapeutics receives a no objection letter from Health Canada for a Phase I Trial of ACCUM-002 (AccuTOX) as an anti-cancer molecule in patients...
Defence’s ARM-X vaccine completely inhibits ovarian cancer growth in treated animals
Defence Therapeutics Inc., a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce that its second-generation ARM-X anti-cancer...
Defence Therapeutics’ AccuTOX® study published in the Journal of Translational Medicine
Defence Therapeutics has announced the publication of a peer-reviewed study on the anti-cancer properties of its unconjugated AccuTOX®.
Chiesi Group forges alliance with Karolinska Institutet to tackle urgent health challenges
The landmark collaboration will accelerate research and development initiatives for respiratory diseases, rare diseases, diseases of prematurity, and other speciality care indications. One of...
Defence Therapeutics strengthens and expands global patent protection on key technologies
Defence Therapeutics Inc. has announced the issuance of several new patents and new allowances of patent applications belonging to different Patent Families in Defence’s...
Global collaboration announced to develop seralutinib for pulmonary hypertension
Chiesi Farmaceutici and Gossamer Bio Inc have entered into a global collaboration to develop seralutinib for pulmonary hypertension treatment.
Trial demonstrates ARM-002TM vaccine’s effectiveness against pancreatic cancer
Defence Therapeutics has announced a successful pre-clinical vaccination trial utilising its ARM-002TM vaccine against pancreatic cancer.
ARM-002TM anti-cancer vaccine shows promise in combatting pre-established melanoma
Defence Therapeutics Inc. has unveiled the exceptional efficacy of its second-generation ARMTM anti-cancer vaccine.
The anti-cancer vaccine, dubbed ARM-002TM, has demonstrated proficiency in combating pre-established...
Chiesi Group celebrates €3bn sales success in 2023
Chiesi Group, a renowned biopharmaceutical powerhouse headquartered in Parma, Italy, revealed €3bn in sales in 2023, a significant growth from the previous year.
With 31...
B Medical Systems’ TCW40SDD receives ACT label from My Green Lab
B Medical Systems, an industry leader in the medical cold chain sector, has received the prestigious ACT label from My Green Lab for its...